Is a Form 483 the same as a Warning Letter?

No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.

Where can I read the full Form 483?

The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.

What is an FDA Form 483?

A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.

Does this Form 483 mean Cohance Lifesciences Limited violated the law?

No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

FDA Inspects Cohance Lifesciences Limited: Form 483 with 5 Citations (August 12, 2025)

FDA inspected Cohance Lifesciences Limited in India and issued a Form 483 listing 5 inspectional observations following an inspection that concluded 2025-08-12. FDA records classify Cohance Lifesciences Limited as a finished pharmaceutical manufacturer. A Form 483 documents an investigator's findings at the close of an inspection under the Federal Food, Drug, and Cosmetic Act; it is not a final agency compliance determination. The observations on this page are drawn directly from the FDA-issued Form 483 record.

Key facts

Firm	Cohance Lifesciences Limited
FEI / inspection ID	3008768274
Inspection end date	August 12, 2025
Citation count	5

What a Form 483 means

A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

Citations explained

Observation 1 — There is a failure to thoroughly review any unexplained discrepancy and the

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of i ts componen ts to meet any of its specifications whether or not the batch has been ah-eady distribute d. Specifically, (bTC, A) There is no documentation on the disoosition status and reconc i!i ation of a[ J)rg, imately. of rejecteg J (bT'i tablets, (bJ mg, Batch No. [_ "~ that have gone missing after being rej ected on August 23 , 2023, as J)aJ.i of Deviation DEV/NCR/23/00 33 , Deviation Initiation Date: June 19, 2023. Specifically, r ·- (b>1 4j 4 total containers, which consi~ts of l• ,c 4 l2f Batch N o. I CtiTC lcompressed ta blets, had fallen on the fl oor from the (b)l1 during transfer from the hold ru.·e a to Bottle packing lin~ (b)1-4j According to the final investigation repo1i, the decision was ma de to destroy the entire batch due to the high number.

Observation 2 — Written records of investigation of a diug complaint do not include the

Written records of investigation of a diug complaint do not include the follow-up. Specifica lly, A) Co mplaint #PC/ NCR / FDF/ 23-02 0, was fi led on Octo ber 5th , 2023 tor i (b)1-41 we, tablets USRtli>14 mg, due to the firm 's customer receiving a complai nt from EMPLOYEE(S) SI GNATURE DATE ISSUED Gu erlain Ulysse, I nves t iga t or 8/ 1 2/2025 SEE REVERSE ............ OF THIS PA GE ~se'¾OUE.FI.ANE. 0.8~0HN02S -,,,..... X PAGE 3 of !? PAGES FORM FDA ~83 (09/ 08) PREVIOUS EDmON OBSOLEJE INS PEC TIONAL OBSERVATIONS

Observation 3 — The responsibilities and procedures applicable to the quality control unit are not

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed. Specifically, A) Complaint investigations that are involved with field a le1t rep o1ting activities are not logged into the Field Ale1t Repo1t Log (Annexure I) for fuit her follow-up and reference as per SOP QA084- 02, Field Ale1t Rep o1t, Effective Date: December 31 , 2022, requirement. This include the lack of documentation in the Field Ale1t Repo1t Log for Complaint MC/036/20, Complaint Received on: December 04, 2020 by the customer for I lbH41 Tablets ~ mg, Batch No. I lb>1 4 j Manufacturing, Date: 01 /2020, Exp. Date: I lb> j due to ~ihaimacist stating that one completed seal bottle had ~ tablets under the strengtli o \ lb>< 4 j mg and ~ tablet under the strength of E:}mg, Initial FAR Date: December 08 , 2020, Final FAR Date: December 08 , 2020. According to General Manager of Quality Assurance (QA),.

Observation 4 — Equipment and utensils are not clean ed, maintained and sanitized at appropriate

Equipment and utensils are not clean ed, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safe ty, identity, strength, quality or purity of the diug product. Specifically, A) During the inspectional walkthrough on August 4th. 2025 visible I wci stains were observed within I CbTCl P D, Cb)l1 01 I CbTC1 and behind the I CbYt4j which remains open during CbH operations fo r diug products inte nded fo r the U. S and other 1 bal markets. PilCb114101 was last used to manufacture I CbT<1 4 CbTC4l tablets ~ mg, ~~ mg, and rY{ ~mg, Batch N o. L \U/\~iprior to Product Changeover ype-B) cleanmg bemg completedon July 30, 2025. However, the fo llowing test results were repo1ted a ft er swab sampling perfo1med as per the cunent inspection request fo r the same SEE REVERSE OF THIS PAGE EMPLOYEE(S) SI GNATURE Guerlain Ulysse, I nves t iga t or DATE ISSUED 8/ 1.

Observation 5 — The accuracy, sensitivity, specifi city and rep ro ducibi li ty of

The accuracy, sensitivity, specifi city and rep ro ducibi li ty of test methods have not been estab li shed. Speci fi cally, A) The ,--- (bTC4l analytical method fo r (bY{4 Tablets USP ~ mg, r:Tc 4) mg, ~ mg t,j mg, and (b)(4 mg, which is routinely used for in-process testing, has not been evaluated fo r accuracy, sensitivity, specificity and rep ro ducibility according to the Assistant General Manager of QA. This includes that lack of evaluation fo r the (b)(4 sample preparation procedure and suitability of sample mass di fferences. For exampl e:

Cohance Lifesciences Limited’s FDA history

Argus HQ has recorded 1 total FDA action tied to Cohance Lifesciences Limited: 0 warning letters, 0 recalls, 0 approval records, and 1 Form 483 inspection citation.

Frequently asked questions

Is a Form 483 the same as a Warning Letter?: No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.
Where can I read the full Form 483?: The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.
What is an FDA Form 483?: A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.
Does this Form 483 mean Cohance Lifesciences Limited violated the law?: No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

See if this 483 escalates to a warning letter — before your auditor asks.

Free weekly briefing tracks every FDA inspection outcome.

Full FDA history for Cohance Lifesciences Limited

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2025). FDA Inspects Cohance Lifesciences Limited: Form 483 with 5 Citations (August 12, 2025). Digital Empire LLC. Retrieved from https://argushq.ai/483/fda-483-cohance-lifesciences-limited-2025-08-12-3008768274

MLA

"FDA Inspects Cohance Lifesciences Limited: Form 483 with 5 Citations (August 12, 2025)." Argus HQ Research, Digital Empire LLC, 2025, argushq.ai/483/fda-483-cohance-lifesciences-limited-2025-08-12-3008768274.

Chicago

Argus HQ Research. "FDA Inspects Cohance Lifesciences Limited: Form 483 with 5 Citations (August 12, 2025)." Digital Empire LLC. Accessed July 15, 2026. https://argushq.ai/483/fda-483-cohance-lifesciences-limited-2025-08-12-3008768274.

BibTeX

@misc{argushq_argushq_ai_483_fda_483_cohance_lifesciences_limited_2025_08_12_3008768274_2025,
  title = {FDA Inspects Cohance Lifesciences Limited: Form 483 with 5 Citations (August 12, 2025)},
  author = {{Argus HQ Research}},
  year = {2025},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/483/fda-483-cohance-lifesciences-limited-2025-08-12-3008768274},
  note = {Accessed: July 15, 2026}
}

Source: FDA.gov — Inspection Classification Database ↗